AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Capricor 2025 Q3 Earnings Net Loss Widens 95.7% to $24.57M Amid Ongoing Financial Struggles
Generated by AI AgentDaily EarningsReviewed byAInvest News Editorial Team
Tuesday, Nov 11, 2025 3:13 am ET1min read
Aime Summary, matching Wall Street estimates. , driven by increased R&D expenses. , with no revenue anticipated in 2025.
Revenue
, .
Earnings/Net Income
. Meanwhile, , . , underscoring ongoing financial challenges.
Price Action
Following the earnings report, , , . However, . The mixed price action reflects investor uncertainty amid the company’s financial challenges and high-stakes regulatory prospects.
CEO Commentary
, Co-Founder, President, CEO & Director, emphasized Capricor’s focus on the impending top-line data from the HOPE-3 Phase III trial of deramiocel for Duchenne muscular dystrophy, calling it a “major milestone” and a “decade-long scientific development” aimed at addressing unmet needs in non-ambulant patients. She highlighted the trial’s rigorous design, including 105 participants across two cohorts to validate commercial-scale manufacturing efficacy, and reiterated deramiocel’s strong safety profile across 150 patients. Strategic priorities included leveraging the FDA’s regulatory flexibility to submit HOPE-3 data as a CRL response, preparing for commercialization with a fully operational San Diego GMP facility, and advancing physician education and market access. Marbán expressed optimism about potential 2026 FDA approval, prioritizing cardiomyopathy labeling before skeletal expansion, .
Guidance
, CFO & Corporate Treasurer, , sufficient to fund operations through Q4 2026. He noted Q3 2025 revenue was $0, , due to the full recognition of the 2024 Nippon Shinyaku distribution agreement. , , driven by HOPE-3 trial execution and manufacturing readiness. , 2026.
Additional News
Capricor announced FDA regulatory flexibility for its Duchenne therapy resubmission, with potential 2026 approval. , 2026. Additionally, the (RMAT) designation was highlighted as a strategic advantage. A shareholder lawsuit was also announced, alleging insider misstatements regarding the drug’s safety data. The SEC 10-Q filing detailed ongoing financial challenges, .
Daily Earnings
Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.
Latest Articles
Nutanix 2026 Q1 Earnings Record Net Income Surges 107.5%
Dec.05 2025
Hormel Foods 2025 Q4 Earnings Net Loss Amid EPS Beat and Guidance Raise
Dec.05 2025
DocuSign 2026 Q3 Earnings Beats Expectations with 34.1% Net Income Growth
Dec.05 2025
Sprinklr 2026 Q3 Earnings Revenue Beats Estimates, EPS Drops 75%
Dec.05 2025
Salesforce 2026 Q3 Earnings Net Income Surges 36.6% on AI-Driven Growth
Dec.05 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet